PMID- 29410368
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20181202
IS  - 1872-7913 (Electronic)
IS  - 0924-8579 (Linking)
VI  - 51
IP  - 6
DP  - 2018 Jun
TI  - Surveillance of tigecycline activity tested against clinical isolates from a
      global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
PG  - 848-853
LID - S0924-8579(18)30009-8 [pii]
LID - 10.1016/j.ijantimicag.2018.01.006 [doi]
AB  - Tigecycline and comparators were tested by the reference broth microdilution
      method against 33 348 non-duplicate bacterial isolates collected prospectively in
      2016 from medical centres in the Asia-Pacific (3443 isolates), Europe (13 530
      isolates), Latin America (3327 isolates) and the USA (13 048 isolates). Among
      7098 Staphylococcus aureus isolates tested, >99.9% were inhibited by </=0.5 mg/L 
      tigecycline (MIC50/90, 0.06/0.12 mg/L), including >99.9% of methicillin-resistant
      S. aureus and 100.0% of methicillin-susceptible S. aureus. Tigecycline was
      slightly more active against Enterococcus faecium (MIC50/90, 0.03/0.06 mg/L)
      compared with Enterococcus faecalis (MIC50/90, 0.06/0.12 mg/L) and its activity
      was not adversely affected by vancomycin resistance when tested against these
      organisms. Tigecycline potency was comparable for Streptococcus pneumoniae
      (MIC50/90, 0.03/0.06 mg/L), viridans group streptococci (MIC50/90, 0.03/0.06
      mg/L) and beta-haemolytic streptococci (MIC50/90, 0.06/0.06 mg/L) regardless of
      species and penicillin susceptibility. Tigecycline was active against
      Enterobacteriaceae (MIC50/90, 0.25/1 mg/L; 97.8% inhibited at </=2 mg/L) but was 
      slightly less active against Enterobacteriaceae isolates expressing resistant
      phenotypes: carbapenem-resistant Enterobacteriaceae (MIC50/90, 0.5/2 mg/L; 98.0% 
      susceptible); multidrug-resistant (MIC50/90, 0.5/2 mg/L; 93.1% susceptible); and 
      extensively drug-resistant (MIC50/90, 0.5/4 mg/L; 87.8% susceptible). Tigecycline
      inhibited 74.4% of 888 Acinetobacter baumannii isolates at </=2 mg/L (MIC50/90,
      2/4 mg/L) and demonstrated good in vitro activity against Stenotrophomonas
      maltophilia (MIC50/90, 1/2 mg/L; 90.6% inhibited at </=2 mg/L) Tigecycline was
      active against Haemophilus influenzae (MIC50/90, 0.12/0.25 mg/L) regardless of
      beta-lactamase status. Tigecycline represents an important treatment option for
      resistant Gram-negative and Gram-positive bacterial infections.
CI  - Copyright (c) 2018 Elsevier B.V. and International Society of Chemotherapy. All
      rights reserved.
FAU - Pfaller, Michael A
AU  - Pfaller MA
AD  - JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA
      52317, USA; University of Iowa, Iowa City, Iowa, USA.
FAU - Huband, Michael D
AU  - Huband MD
AD  - JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA
      52317, USA.
FAU - Streit, Jennifer M
AU  - Streit JM
AD  - JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA
      52317, USA.
FAU - Flamm, Robert K
AU  - Flamm RK
AD  - JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA
      52317, USA.
FAU - Sader, Helio S
AU  - Sader HS
AD  - JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA
      52317, USA. Electronic address: helio-sader@jmilabs.com.
LA  - eng
PT  - Journal Article
DEP - 20180202
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (Anti-Bacterial Agents)
RN  - 70JE2N95KR (Tigecycline)
RN  - FYY3R43WGO (Minocycline)
SB  - IM
MH  - Acinetobacter baumannii/drug effects/isolation & purification
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Asia
MH  - Carbapenem-Resistant Enterobacteriaceae/drug effects/isolation & purification
MH  - Drug Resistance, Multiple, Bacterial
MH  - Enterococcus faecium/drug effects/isolation & purification
MH  - Europe
MH  - Gram-Negative Bacterial Infections/*drug therapy
MH  - Gram-Positive Bacterial Infections/*drug therapy
MH  - Haemophilus influenzae/drug effects/isolation & purification
MH  - Humans
MH  - Latin America
MH  - Methicillin-Resistant Staphylococcus aureus/drug effects/isolation & purification
MH  - Microbial Sensitivity Tests
MH  - Minocycline/*analogs & derivatives/pharmacology
MH  - North America
MH  - Prospective Studies
MH  - Stenotrophomonas maltophilia/drug effects/isolation & purification
MH  - Streptococcus pneumoniae/drug effects/isolation & purification
MH  - Tigecycline
OTO - NOTNLM
OT  - Antimicrobial resistance
OT  - CRE
OT  - Enterobacteriaceae
OT  - MRSA
OT  - Staphylococcus aureus
OT  - VRE
EDAT- 2018/02/08 06:00
MHDA- 2018/10/12 06:00
CRDT- 2018/02/08 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2018/01/09 00:00 [revised]
PHST- 2018/01/14 00:00 [accepted]
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2018/02/08 06:00 [entrez]
AID - S0924-8579(18)30009-8 [pii]
AID - 10.1016/j.ijantimicag.2018.01.006 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi:
      10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.